Home
HelpTest Code NGSHM MayoComplete Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation Sequencing, Varies
Useful For
Evaluation of known or suspected hematologic neoplasms, specifically of myeloid origin (eg, acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, myelodysplastic/myeloproliferative neoplasm, unexplained cytopenias) at the time of diagnosis or possibly disease relapse
Aiding in determining diagnostic classification
Providing prognostic or therapeutic information for helping guide clinical management
Evaluating patients with suspected VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome
Determining the presence of new clinically important gene mutation changes at relapse
Highlights
Next-generation sequencing detection of somatic gene mutations, including type, pattern, and distribution, has diagnostic, prognostic, and potential therapeutic implications for patients with hematologic cancers of myeloid origin.
Testing Algorithm
For more information see:
-Acute Leukemias of Ambiguous Lineage Testing Algorithm
-Acute Myeloid Leukemia: Testing Algorithm
-Acute Myeloid Leukemia: Relapsed with Previous Remission Algorithm
-Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation
Special Instructions
- Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation
- Hematopathology Patient Information
- Acute Leukemias of Ambiguous Lineage Testing Algorithm
- Acute Myeloid Leukemia: Testing Algorithm
- Acute Myeloid Leukemia: Relapsed with Previous Remission Algorithm
- Mast Cell Disorder: Diagnostic Algorithm, Bone Marrow
- Targeted Genes Interrogated by Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation Sequencing
Method Name
Next-Generation Sequencing (NGS)
Reporting Name
Myeloid Neoplasms, NGS, VSpecimen Type
VariesShipping Instructions
Peripheral blood and bone marrow specimens must arrive within 14 days of collection.
Necessary Information
The following information is required:
1. Clinical diagnosis
2. Pertinent clinical history, including disease phase (diagnostic, remission, relapse/refractory) and therapy status (especially if patient has received a hematopoietic stem cell transplant).
3. Clinical or morphologic suspicion
4. Date of collection
5. Specimen source
Specimen Required
Submit only 1 of the following specimens:
Preferred Specimen Type: Bone marrow aspirate
Container/Tube:
Preferred: Lavender top (EDTA) or yellow top (ACD)
Acceptable: Green top (sodium heparin)
Specimen Volume: 2 mL
Collection Instructions:
1. Invert several times to mix bone marrow.
2. Send bone marrow specimen in original tube. Do not aliquot.
3. Label specimen as bone marrow.
Specimen Stability: Ambient (preferred)/Refrigerate
Specimen Type: Whole blood
Container/Tube:
Preferred: Lavender top (EDTA) or yellow top (ACD)
Acceptable: Green top (sodium heparin)
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
3. Label specimen as blood.
Specimen Stability: Ambient (preferred)/Refrigerate
Specimen Type: Extracted DNA from blood or bone marrow
Container/Tube: 1.5- to 2-mL tube with indication of volume and concentration of the DNA
Specimen Volume: Entire specimen
Collection Instructions: Label specimen as extracted DNA and source of specimen
Specimen Stability: Frozen (preferred)/Refrigerate/Ambient
Specimen Minimum Volume
Blood, Bone marrow: 1 mL
Extracted DNA: 100 mcL at 20 ng/mcL concentration
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Varies | Varies | 14 days |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | OK |
| Bone marrow biopsies Slides Paraffin shavings or frozen tissues Paraffin-embedded tissues Paraffin-embedded bone marrow aspirates Moderately to severely clotted |
Reject |
Clinical Information
Next-generation sequencing is a comprehensive molecular diagnostic methodology that can interrogate multiple regions of genomic tumor DNA in a single assay. Many hematologic neoplasms are characterized by morphologic or phenotypic similarities but can have characteristic somatic mutations in many genes that enable more specific categorization. In addition, many myeloid neoplasms lack a clonal cytogenetic finding at diagnosis (normal karyotype) but can be diagnosed or confirmed and classified according to the gene mutation profile. Patients with unexplained cytopenias may harbor acquired genetic alterations in hematopoietic cells (clonal cytopenias of uncertain significance), which may carry risk of developing overt myeloid malignancies. The presence and pattern of gene mutations in known or suspected myeloid neoplasm can provide critical diagnostic, prognostic, and therapeutic information to help guide management for the patient's physician. Patients presenting with severe inflammatory features, often with cytopenias, may have VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome and can be identified by the presence of somatic UBA1 gene mutation.
Reference Values
An interpretive report will be provided.
Interpretation
Detailed variant assessment and interpretive comments will be provided for all reportable genetic alterations.
If this test is ordered in the setting of erythrocytosis and suspicion of polycythemia vera, interpretation requires correlation with a concurrent or recent prior bone marrow evaluation.
Method Description
Next-generation sequencing is performed for the presence of a mutation in targeted regions of 47 genes. For details regarding the targeted gene regions identified in this test see Targeted Genes Interrogated by Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation Sequencing. Extracted DNA from the clinical specimen is fragmented, adapter ligated, and a sequence library of fragments is prepared using a custom capture hybridization method. Individual patient samples are indexed ("bar-coded") for identification, and the library is sequenced on an Illumina platform. Sequence data are processed through a bioinformatics pipeline, and a variant call file is generated for final analysis and reporting.(Unpublished Mayo method)
Genes analyzed: ANKRD26, ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CEBPA, CSF3R, DDX41, DNMT3A, ELANE, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, KDM6A, KIT, KRAS, MPL, NF1, NPM1, NRAS, PHF6, PPM1D, PTPN11, RAD21, RUNX1, SETBP1, SH2B3, SF3B1, SMC3, SRSF2, STAG2, STAT3, TERT, TET2, TP53, U2AF1, UBA1, WT1, and ZRSR2
Day(s) Performed
Monday through Friday
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81450
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| NGSHM | Myeloid Neoplasms, NGS, V | In Process |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| MP024 | Specimen Type | 31208-2 |
| NGSD | Indication for Test | 42349-1 |
| 601696 | NGSHM Result | No LOINC Needed |
| 37276 | Pathogenic Mutations Detected | 82939-0 |
| 37283 | Interpretation | 69047-9 |
| 37282 | Clinical Trials | 82786-5 |
| 37277 | Variants of Unknown Significance | 93367-1 |
| 37278 | Additional Notes | 48767-8 |
| 37279 | Method Summary | 85069-3 |
| 37420 | Disclaimer | 62364-5 |
| 37280 | OncoHeme Panel Gene list | 36908-2 |
| 37287 | Reviewed By: | 18771-6 |
Forms
1. Hematopathology Patient Information (T676)
2. If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726) with the specimen.